
Sanara Medtech Inc SMTI.OQ SMTI.O is expected to show a rise in quarterly revenue when it reports results on May 14 for the period ending March 31 2025
The Fort Worth Texas-based company is expected to report a 26.6% increase in revenue to $23.475 million from $18.54 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.
LSEG's mean analyst estimate for Sanara Medtech Inc is for a loss of 50 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Sanara Medtech Inc is $48.50, above its last closing price of $32.35.
This summary was machine generated May 12 at 13:15 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)